Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 13/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | FPR3 | P25089 | 1/20 | 0.33 |
| ▸ | TSPO | P30536 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7556757 | 0.86 | CRHR1 (0.39) | CRHR1TDP1LMNAFPR3TSPO | |
| SCHEMBL7560082 | 0.84 | CRHR1 (0.53) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL7557332 | 0.81 | CRHR1 (0.41) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL7558601 | 0.78 | CRHR1 (0.62) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL7573155 | 0.78 | CRHR1 (0.39) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL7217519 | 0.78 | CRHR1 (0.53) | CRHR1TDP1 | |
| SCHEMBL7554926 | 0.77 | CRHR1 (0.39) | CRHR1TDP1LMNA | |
| SCHEMBL7554709 | 0.77 | CRHR1 (0.47) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL7554234 | 0.73 | CRHR1 (0.69) | CRHR1TDP1 | |
| SCHEMBL7217860 | 0.72 | CRHR1 (0.49) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019406-A1 | 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands | NEUROGEN CORPORATION | 2002-02-14 | — | — | US | claimed |
| US-20020019406-A1 | 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands | NEUROGEN CORPORATION | 2002-02-14 | — | — | US | disclosed |
| US-6284766-B1 | DIAGNOSIS, THERAPY OF STRESS DISORDERS | NEUROGEN CORPORATION | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019406-A1 | 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands | HTR1D, CRHR1, HTR1A | CRHR1 2/4885TDP1 2969/4885LMNA 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.